LEXX Lexaria Bioscience Corp.
Financings ·
Lexaria Bioscience cut the exercise price on 453,969 existing warrants to $12.92 a share, for about $5.9 million in gross proceeds. In return it issued two new warrant series, each for the same number of shares, at $12.67.
The warrants will be exercised at $12.92 per share for gross proceeds of about $5.9 million, with H.C. Wainwright & Co. as exclusive placement agent. Holders receive new Series A and Series B warrants at $12.67.
The Hearings Advisor told the company on August 17, 2026 that staff confirmed compliance with Listing Rule 5550(a)(2), and the requested hearing was cancelled.
Shares outstanding will drop from 24,787,446 to 1,652,518. The company expects to seek a Nasdaq hearing if it gets a delisting notice.
Lexaria sold 2,661,600 shares at $1.315 in a registered direct offering and placed matching warrants at $1.19, for about $3.5 million gross. H.C. Wainwright & Co., LLC was placement agent. Its annual report says the company has substantial doubt about continuing as a going concern.
Lexaria Bioscience Corp. is a biotechnology company dedicated to enhancing the bioavailability of a broad range of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH combines active ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds, and it can be built into oral suspensions, tablets, capsules, foods, beverages and oral pouches. The active molecules include GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids. The company says its primary focus is pharmaceutical drug products, and it also supports licensees in integrating the technology into their own products. The therapeutic areas named include diabetes, weight loss, epilepsy, hypertension and heart disease. The company says it has been allowed or granted 56 patents worldwide. The technology dates back to a 2014 relationship with Poppy's Teas LLC, which later became Poviva Corp., a wholly owned subsidiary that is the named owner of the DehydraTECH patents. Lexaria holds an exclusive license to use the technology from Poviva. The company also has a cleared Investigational New Drug application with the FDA for a cannabinoid program in heart disease and hypertension.
| Product or program | What it is | Stage |
|---|---|---|
| DehydraTECH | Patented drug delivery technology that improves the bioavailability of active ingredients | |
| GLP-1 and GIP program | DehydraTECH formulations for diabetes and weight loss | ongoing and expanding cardiometabolic clinical research |
| Cannabinoid program | DehydraTECH with cannabinoids for heart disease and hypertension | cleared IND application with the FDA |
| Line | FY ended Aug 31, 2025 | FY ended Aug 31, 2024 |
|---|---|---|
| Revenue | $705,923 | $464,278 |
| Research and development | $8.2 million | $2.4 million |
| Net income (loss) | -$11.9 million | -$5.8 million |
| Cash from operations | -$10.5 million | -$5.0 million |
| Cash and equivalents | $1.8 million | $6.5 million |
| Short-term investments | $143,267 | $55,807 |
Our latest story on this, dated Jul 30, 2026: "Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 30, 2026: "Lexaria sets 1-for-15 reverse split for August 3, 2026 to meet Nasdaq bid rule". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 16, 2025: "Lexaria closes registered direct offering and warrant placement for about $3.5 million gross". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Dec 16, 2025: "Lexaria closes registered direct offering and warrant placement for about $3.5 million gross". The story links the filing or release it is based on. Read the story.
Lexaria Bioscience Corp. trades under the ticker LEXX on NASDAQ.
Lexaria Bioscience Corp. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lexaria Bioscience Corp. is 1348362. Its filings are on SEC EDGAR.
24,787,446 shares as of 2026-07-13, per the cover page of its 10-Q filed 2026-07-13.
Our directory records Lexaria Bioscience Corp. under Canada.
Our directory classifies Lexaria Bioscience Corp. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lexaria Bioscience Corp. is US52886N6040.
aibio.space lists Lexaria Bioscience Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
Lexaria Bioscience Corp. is a biotechnology company dedicated to enhancing the bioavailability of a broad range of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH combines active ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds, and it can be built into oral suspensions, tablets, capsules, foods, beverages and oral pouches.
DehydraTECH: Patented drug delivery technology that improves the bioavailability of active ingredients
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio